Colchicine-intolerant familial mediterranean fever patients: A comparative study between different colchicine doses and IL-1 inhibitor monotherapy.

Colchicine Colchicine intolerance Familial Mediterranean fever IL-1 antagonists Monotherapy Treatment

Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
18 Jan 2024
Historique:
received: 02 08 2023
revised: 01 01 2024
accepted: 02 01 2024
medline: 20 1 2024
pubmed: 20 1 2024
entrez: 19 1 2024
Statut: aheadofprint

Résumé

Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease. Colchicine is the primary treatment for FMF, although some patients do not respond well or are unable to tolerate it. For these patients, the addition of interleukin-1 (IL-1) antagonists is the preferred option. However, the impact of colchicine treatment alongside the use of IL-1 antagonists remains unclear. We recruited adult FMF patients who satisfied the Eurofever and Pediatric Rheumatology International Trials Organization classification criteria and were receiving IL-1 antagonist treatment from our FMF cohort. All the patients exhibited colchicine intolerance or resistance. As per the FMF cohort protocol, the patients were longitudinally followed up, including assessments of their C-reactive protein, erythrocyte sedimentation rate, autoinflammatory disease activity index (AIDAI), and autoinflammatory damage index (ADDI). Among the 125 patients (68 female and 57 male), 96 received a combination of IL-1 antagonists and the maximum tolerated dose of colchicine, whereas 29 were treated exclusively with IL-1 antagonists due to colchicine intolerance. The patients' inflammatory markers, AIDAI activity, and ADDI damage scores did not differ significantly between the two groups during the follow-up period. Notably, the drug retention rates were significantly higher in the patients treated solely with IL-1 antagonists. While the typical approach is to maintain colchicine treatment alongside the use of IL-1 antagonists, for patients who cannot tolerate effective colchicine doses, IL-1 antagonists alone may effectively control FMF disease activity.

Identifiants

pubmed: 38241844
pii: S1567-5769(24)00008-0
doi: 10.1016/j.intimp.2024.111491
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111491

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. No funding was obtained for this study

Auteurs

Derya Yildirim (D)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey. Electronic address: deryaakdeniz1@gmail.com.

Riza Can Kardas (RC)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Mert Gun (M)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Burcugul Kaya (B)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Ibrahim Vasi (I)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Rahime Duran (R)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Hazan Karadeniz (H)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Aslihan Avanoglu Guler (A)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Hamit Kucuk (H)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Abdulsamet Erden (A)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Berna Goker (B)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Mehmet Akif Ozturk (MA)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Abdurrahman Tufan (A)

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Turkey.

Classifications MeSH